Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 4, Number 1—March 1998

Proteases of Malaria Parasites: New Targets for Chemotherapy

Philip J. RosenthalComments to Author 
Author affiliation: San Francisco General Hospital and University of California, San Francisco, California, USA

Main Article

Table 2

New antimalarial drugs

Drug Role Best Feature(s) Limitations
Halofantrine TX of Pf malaria; not approved for CP Usually effective against R Pf malaria Variable bioavailability, cardiac toxicity
Artemisinin and related compoundsa TX of Pf malaria Rapidly acting; effective against multidrug-R strains Recurrence after TX fairly common
Atovaquone ? TX of Pf malaria; ? CP (probably in combination with proguanil) Limited toxicity Limited studies so far show frequent recurrence after TX
Pyronaridinea ? TX of Pf malaria Effective against R strains Studies limited to date
Desferrioxamine ? TX of severe Pf malaria Well tolerated when used for iron overload Studies limited to date
Azithromycin ? CP Limited toxicity Studies limited to date

For abbreviations, see Table 1, footnote a.
aNot available in the United States.

Main Article

Page created: December 13, 2010
Page updated: December 13, 2010
Page reviewed: December 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.